Madrigal Pharmaceuticals, Inc.
MDGL
Rangering i aksjer
#1965
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Aksjekurs
$463.61
Markedsverdi
$10.71B
Endring (1 dag)
3.70%
Endring (1 år)
5.37%
Land
US
Handel Madrigal Pharmaceuticals, Inc. (MDGL)
Kategori
Healthcare
P/S-forhold for Madrigal Pharmaceuticals, Inc. (MDGL)
P/S-forhold per October 2026 TTM: 8.28
Ifølge Madrigal Pharmaceuticals, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 8.28. Ved slutten av 2023 hadde selskapet et P/S-forhold på 0.00.
P/S-historikk for Madrigal Pharmaceuticals, Inc. fra 2001 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 8.28 | -77.28% |
| 2024 | 36.44 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | -100.00% |
| 2011 | 29.05 | 74.13% |
| 2010 | 16.68 | 1,303.55% |
| 2009 | 1.19 | -98.49% |
| 2008 | 78.95 | -73.03% |
| 2007 | 292.76 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | -100.00% |
| 2004 | 982.75 | 545.13% |
| 2003 | 152.33 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 10.02 | 21.07% |
US
|
|
| 40.55 | 389.88% |
US
|
|
| 3.96 | -52.15% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 22.57% |
NL
|
